Cubist Systematic Strategies LLC Makes New Investment in Aldeyra Therapeutics, Inc (NASDAQ:ALDX)

Cubist Systematic Strategies LLC acquired a new position in shares of Aldeyra Therapeutics, Inc (NASDAQ:ALDX) during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 5,072 shares of the biotechnology company’s stock, valued at approximately $30,000.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. Algert Global LLC grew its stake in Aldeyra Therapeutics by 28.6% during the 2nd quarter. Algert Global LLC now owns 29,840 shares of the biotechnology company’s stock valued at $179,000 after acquiring an additional 6,631 shares in the last quarter. Private Advisors LLC grew its stake in Aldeyra Therapeutics by 21.8% during the 2nd quarter. Private Advisors LLC now owns 40,270 shares of the biotechnology company’s stock valued at $242,000 after acquiring an additional 7,211 shares in the last quarter. Charles Schwab Investment Management Inc. grew its stake in Aldeyra Therapeutics by 47.5% during the 2nd quarter. Charles Schwab Investment Management Inc. now owns 61,536 shares of the biotechnology company’s stock valued at $370,000 after acquiring an additional 19,826 shares in the last quarter. Mesirow Financial Investment Management Inc. grew its stake in Aldeyra Therapeutics by 12.1% during the 2nd quarter. Mesirow Financial Investment Management Inc. now owns 62,736 shares of the biotechnology company’s stock valued at $373,000 after acquiring an additional 6,775 shares in the last quarter. Finally, Strs Ohio grew its stake in Aldeyra Therapeutics by 7.5% during the 2nd quarter. Strs Ohio now owns 71,900 shares of the biotechnology company’s stock valued at $431,000 after acquiring an additional 5,000 shares in the last quarter. Hedge funds and other institutional investors own 61.26% of the company’s stock.

Several equities analysts have weighed in on ALDX shares. Zacks Investment Research raised Aldeyra Therapeutics from a “sell” rating to a “hold” rating in a research note on Monday, October 14th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Aldeyra Therapeutics in a research note on Thursday. Finally, ValuEngine raised Aldeyra Therapeutics from a “hold” rating to a “buy” rating in a research note on Tuesday, September 10th. Two research analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. Aldeyra Therapeutics currently has a consensus rating of “Buy” and an average target price of $24.19.

In other news, Director Richard Douglas purchased 20,000 shares of the stock in a transaction that occurred on Tuesday, September 10th. The stock was acquired at an average price of $5.00 per share, with a total value of $100,000.00. Following the purchase, the director now owns 70,000 shares in the company, valued at approximately $350,000. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Todd C. Brady purchased 10,000 shares of the stock in a transaction that occurred on Monday, September 9th. The stock was purchased at an average cost of $4.89 per share, with a total value of $48,900.00. Following the purchase, the chief executive officer now owns 50,000 shares in the company, valued at approximately $244,500. The disclosure for this purchase can be found here. In the last three months, insiders purchased 83,907 shares of company stock valued at $456,912. 13.50% of the stock is currently owned by company insiders.

NASDAQ:ALDX opened at $5.66 on Friday. Aldeyra Therapeutics, Inc has a fifty-two week low of $4.31 and a fifty-two week high of $12.79. The stock’s 50-day moving average is $5.38 and its two-hundred day moving average is $6.35. The stock has a market cap of $163.82 million, a PE ratio of -3.16 and a beta of 0.86.

Aldeyra Therapeutics (NASDAQ:ALDX) last released its earnings results on Thursday, August 8th. The biotechnology company reported ($0.49) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.51) by $0.02. Sell-side analysts forecast that Aldeyra Therapeutics, Inc will post -1.92 EPS for the current year.

About Aldeyra Therapeutics

Aldeyra Therapeutics, Inc, a biotechnology company, focuses on the development of products for inflammation, inborn errors of metabolism, and other diseases in the United States and internationally. It is developing ADX-102, a small molecule designed to trap and allow for the degradation of aldehydes, as well as ADX-103 and ADX-104 novel candidates for the treatment of noninfectious anterior uveitis, allergic conjunctivitis, dry eye syndrome, sjögren-larsson syndrome, and succinic semi-aldehyde dehydrogenase deficiency.

Featured Article: What is a Candlestick Chart?

Want to see what other hedge funds are holding ALDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Aldeyra Therapeutics, Inc (NASDAQ:ALDX).

Institutional Ownership by Quarter for Aldeyra Therapeutics (NASDAQ:ALDX)

Receive News & Ratings for Aldeyra Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aldeyra Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.